Результаты комплексного лечения трижды негативного рака молочной железы
https://doi.org/10.17650/1994-4098-2014-0-1-58-65
Аннотация
Об авторах
М. А. СекундоваРоссия
В. И. Борисов
Россия
А. М. Сдвижков
Россия
Список литературы
1. Курс химиотерапии при раке молочной железы. Маммология. Хирургия молочной железы. http://mammalogy.eurodoctor.ru/ chemotherapybreastcancer.
2. Parkin D.M. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer 2009;45(9):1649–53.
3. Audeh W. Reducing the risk of breast cancer. 2010. http://www.beatcancerguam.com/uploads.
4. World cancer report 2008. International Agency for Research on Cancer. Lyon, 2008. р. 64.
5. Bauer K.R., Brown M., Cress R.D. et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)- negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109(9):1721–8.
6. Brenton J.D., Carey L.A., Ahmed A.A., Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23(29):7350–60.
7. Fulford L.G., Reis-Filho J.S., Ryder K. et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long- term survival. Breast Cancer Res 2006;9(1):R4. 8. Carey L.A., Perou C.M., Livasy C.A. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295(21):2492–502.
8. Livasy C.A., Karaca G., Nanda R. et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19(2):264–71.
9. Collett K., Stefansson I.M., Eide J. et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005;14(5):1108–12.
10. Mehta R.S. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple- negative paradox. J Clin Oncol 2008;26(19):3286–8.
11. Rakha E.A., El-Sayed M.E., Green A.R. et al. Prognostic markers in triple-negative breast cancer. Cancer 2007;109(1):25–32.
12. Turner N., Lambros M.B., Horlings H.M. et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010;29(14):2013–23.
Рецензия
Для цитирования:
Секундова М.А., Борисов В.И., Сдвижков А.М. Результаты комплексного лечения трижды негативного рака молочной железы. Опухоли женской репродуктивной системы. 2014;(1):58-65. https://doi.org/10.17650/1994-4098-2014-0-1-58-65
For citation:
Sekundova M.A., Borisov V.I., Sdvizhkov A.M. Results of combination treatment for triple-negative breast cancer. Tumors of female reproductive system. 2014;(1):58-65. (In Russ.) https://doi.org/10.17650/1994-4098-2014-0-1-58-65